New technologies for influenza vaccines

References

• Francis T, Magill TP. The Antibody Response of Human Subjects Vaccinated with the Virus of Human Influenza. J Exp Med 1937; 65:251 - 9; http://dx.doi.org/10.1084/jem.65.2.251; PMID: 19870599
   PubMedGoogle Scholar
• New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009; 84:249 - 57; PMID: 19537358
   PubMedGoogle Scholar
• Experiences with obtaining influenza vaccination among persons in priority groups during a vaccine shortage–United States, October-November, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:1153 - 5; PMID: 15614228
   PubMedGoogle Scholar
• Dormitzer PR. Cell culture-derived influenza vaccines. In: Del Giudice G, Rappuoli R, ed. Influenza Vaccines For the Future. Basel: Birkhauser Inc., 2010:293-312.
   Google Scholar
• Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841 - 8; http://dx.doi.org/10.1086/605505; PMID: 19673651
   PubMed Web of Science ®Google Scholar
• Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010; 28:840 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.10.019; PMID: 19835829
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573 - 84; http://dx.doi.org/10.1056/NEJMoa073121; PMID: 18550874
   PubMed Web of Science ®Google Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424 - 35; http://dx.doi.org/10.1056/NEJMoa0907650; PMID: 19745215
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849 - 57; http://dx.doi.org/10.1086/605506; PMID: 19673652
   PubMed Web of Science ®Google Scholar
• Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20:1240 - 7; http://dx.doi.org/10.1016/S0264-410X(01)00428-5; PMID: 11803087
   PubMed Web of Science ®Google Scholar
• Palache AM, Scheepers HS, de Regt V, van Ewijk P, Baljet M, Brands R, et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev Biol Stand 1999; 98:115 - 25, discussion 33-4; PMID: 10494964
   PubMedGoogle Scholar
• Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997; 176:Suppl 1 S20 - 3; http://dx.doi.org/10.1086/514169; PMID: 9240689
   PubMed Web of Science ®Google Scholar
• Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009; 27:786 - 91; http://dx.doi.org/10.1016/j.vaccine.2008.11.003; PMID: 19027046
   PubMed Web of Science ®Google Scholar
• Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 1998; 16:1331 - 5; http://dx.doi.org/10.1016/S0264-410X(98)00011-5; PMID: 9682398
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Fritsch S, Zeitlinger M, Berezuk G, Low-Baselli A, et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009; 200:1113 - 8; http://dx.doi.org/10.1086/605608; PMID: 19712040
   PubMed Web of Science ®Google Scholar
• Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303:706 - 9; http://dx.doi.org/10.1038/303706a0; PMID: 6190093
   PubMed Web of Science ®Google Scholar
• Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166 - 74; http://dx.doi.org/10.1016/0042-6822(85)90105-9; PMID: 4060580
   PubMed Web of Science ®Google Scholar
• Widjaja L, Ilyushina N, Webster RG, Webby RJ. Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 2006; 350:137 - 45; http://dx.doi.org/10.1016/j.virol.2006.02.020; PMID: 16545416
   PubMed Web of Science ®Google Scholar
• Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990; 64:1808 - 11; PMID: 2319652
   PubMed Web of Science ®Google Scholar
• Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Avian flu: influenza virus receptors in the human airway. Nature 2006; 440:435 - 6; http://dx.doi.org/10.1038/440435a; PMID: 16554799
   PubMed Web of Science ®Google Scholar
• Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 1997; 71:3357 - 62; PMID: 9060710
   PubMed Web of Science ®Google Scholar
• Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009; 27:2907 - 13; http://dx.doi.org/10.1016/j.vaccine.2009.02.064; PMID: 19366582
   PubMed Web of Science ®Google Scholar
• Meguro H, Bryant JD, Torrence AE, Wright PF. Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol 1979; 9:175 - 9; PMID: 219021
   PubMed Web of Science ®Google Scholar
• Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine–Colorado, December 2003. MMWR Morb Mortal Wkly Rep 2004; 53:8 - 11; PMID: 14724559
   PubMedGoogle Scholar
• Update: influenza-associated deaths reported among children aged <18 years–United States, 2003-04 influenza season. MMWR Morb Mortal Wkly Rep 2004; 52:1286 - 8; PMID: 14712178
   PubMedGoogle Scholar
• Cox MM. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 2008; 10:56 - 61; PMID: 18228182
   PubMed Web of Science ®Google Scholar
• Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011; 29:2272 - 8; http://dx.doi.org/10.1016/j.vaccine.2011.01.039; PMID: 21277410
   PubMed Web of Science ®Google Scholar
• Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine 2009; 28:379 - 85; http://dx.doi.org/10.1016/j.vaccine.2009.10.037; PMID: 19879222
   PubMed Web of Science ®Google Scholar
• King JC Jr., Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 2009; 27:6589 - 94; http://dx.doi.org/10.1016/j.vaccine.2009.08.032; PMID: 19716456
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Sahly HE, King J, Graham I, Izikson R, Kohberger R, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok((R))) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine 2011; 29:7733 - 9; http://dx.doi.org/10.1016/j.vaccine.2011.07.128; PMID: 21835220
   PubMed Web of Science ®Google Scholar
• Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635 - 41; http://dx.doi.org/10.1086/590916; PMID: 18694338
   PubMed Web of Science ®Google Scholar
• Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin–one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006; 24:2176 - 85; http://dx.doi.org/10.1016/j.vaccine.2005.11.005; PMID: 16310896
   PubMed Web of Science ®Google Scholar
• Tatu U, Hammond C, Helenius A. Folding and oligomerization of influenza hemagglutinin in the ER and the intermediate compartment. EMBO J 1995; 14:1340 - 8; PMID: 7729412
   PubMed Web of Science ®Google Scholar
• Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982; 31:417 - 27; http://dx.doi.org/10.1016/0092-8674(82)90135-0; PMID: 6186384
   PubMed Web of Science ®Google Scholar
• Wei CJ, Xu L, Kong WP, Shi W, Canis K, Stevens J, et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 2008; 82:6200 - 8; http://dx.doi.org/10.1128/JVI.00187-08; PMID: 18417563
   PubMed Web of Science ®Google Scholar
• Nestorowicz A, Laver G, Jackson DC. Antigenic determinants of influenza virus haemagglutinin. X. A comparison of the physical and antigenic properties of monomeric and trimeric forms. J Gen Virol 1985; 66:1687 - 95; http://dx.doi.org/10.1099/0022-1317-66-8-1687; PMID: 2410559
   PubMed Web of Science ®Google Scholar
• Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 2004; 303:1866 - 70; http://dx.doi.org/10.1126/science.1093373; PMID: 14764887
   PubMed Web of Science ®Google Scholar
• Zhang W, Qi J, Shi Y, Li Q, Gao F, Sun Y, et al. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell 2010; 1:459 - 67; http://dx.doi.org/10.1007/s13238-010-0059-1; PMID: 21203961
   PubMed Web of Science ®Google Scholar
• Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, et al. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS ONE 2011; 6:e20928; http://dx.doi.org/10.1371/journal.pone.0020928; PMID: 21687743
   PubMed Web of Science ®Google Scholar
• Song L, Nakaar V, Kavita U, Price A, Huleatt J, Tang J, et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 2008; 3:e2257; http://dx.doi.org/10.1371/journal.pone.0002257; PMID: 18493310
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS ONE 2010; 5:e11548; http://dx.doi.org/10.1371/journal.pone.0011548; PMID: 20634959
   PubMedGoogle Scholar
• Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373 - 8; http://dx.doi.org/10.1038/289373a0; PMID: 6162101
   PubMed Web of Science ®Google Scholar
• Okuno Y, Isegawa Y, Sasao F, Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993; 67:2552 - 8; PMID: 7682624
   PubMed Web of Science ®Google Scholar
• Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011; 29:4897 - 902; http://dx.doi.org/10.1016/j.vaccine.2011.05.001; PMID: 21596084
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010; 28:8268 - 74; http://dx.doi.org/10.1016/j.vaccine.2010.10.009; PMID: 20969925
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005; 23:5751 - 9; http://dx.doi.org/10.1016/j.vaccine.2005.07.098; PMID: 16143432
   PubMed Web of Science ®Google Scholar
• D'Aoust MA, Lavoie PO, Couture MM, Trepanier S, Guay JM, Dargis M, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008; 6:930 - 40; http://dx.doi.org/10.1111/j.1467-7652.2008.00384.x; PMID: 19076615
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008; 3:e1501; PMID: 18231588
   PubMed Web of Science ®Google Scholar
• Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, et al. H5N1 Virus-Like Particle Vaccine Elicits Cross-Reactive Neutralizing Antibodies That Preferentially Bind to the Oligomeric Form of Influenza Virus Hemagglutinin in Humans. J Virol 2011; 85:10945 - 54; http://dx.doi.org/10.1128/JVI.05406-11; PMID: 21865396
   PubMed Web of Science ®Google Scholar
• Lo´pez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011; 29:7826 - 34; http://dx.doi.org/10.1016/j.vaccine.2011.07.099; PMID: 21816199
   PubMed Web of Science ®Google Scholar
• Landry N, Ward BJ, Trepanier S, Montomoli E, Dargis M, Lapini G, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 2010; 5:e15559; http://dx.doi.org/10.1371/journal.pone.0015559; PMID: 21203523
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008; 2:193 - 202; http://dx.doi.org/10.1111/j.1750-2659.2008.00056.x; PMID: 19453395
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011; 5:67 - 75; http://dx.doi.org/10.1111/j.1750-2659.2010.00183.x; PMID: 21306569
   PubMed Web of Science ®Google Scholar
• Patel SP, Jarvelin MR, Little MP. Systematic review of worldwide variations of the prevalence of wheezing symptoms in children. Environ Health 2008; 7:57; http://dx.doi.org/10.1186/1476-069X-7-57; PMID: 19000318
   PubMed Web of Science ®Google Scholar
• Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260 - 7; http://dx.doi.org/10.1056/NEJMoa0808652; PMID: 19776407
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008; 198:312 - 7; http://dx.doi.org/10.1086/589885; PMID: 18522501
   PubMed Web of Science ®Google Scholar
• Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 2010; 201:354 - 62; http://dx.doi.org/10.1086/649428; PMID: 20039806
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen AC, Pena L, Angel M, Solorzano A, Albrecht R, et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 2009; 83:1742 - 53; http://dx.doi.org/10.1128/JVI.01920-08; PMID: 19073731
   PubMed Web of Science ®Google Scholar
• Zhou B, Li Y, Belser JA, Pearce MB, Schmolke M, Subba AX, et al. NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine 2010; 28:8015 - 25; http://dx.doi.org/10.1016/j.vaccine.2010.08.106; PMID: 20934458
   PubMed Web of Science ®Google Scholar
• Akarsu H, Iwatsuki-Horimoto K, Noda T, Kawakami E, Katsura H, Baudin F, et al. Structure-based design of NS2 mutants for attenuated influenza A virus vaccines. Virus Res 2011; 155:240 - 8; http://dx.doi.org/10.1016/j.virusres.2010.10.014; PMID: 20970464
   PubMed Web of Science ®Google Scholar
• Kopecky-Bromberg SA, Palese P. Recombinant vectors as influenza vaccines. Curr Top Microbiol Immunol 2009; 333:243 - 67; http://dx.doi.org/10.1007/978-3-540-92165-3_13; PMID: 19768410
   PubMedGoogle Scholar
• Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev Vaccines 2009; 8:469 - 81; http://dx.doi.org/10.1586/erv.09.1; PMID: 19348562
   PubMed Web of Science ®Google Scholar
• Zhang J, Tarbet EB, Feng T, Shi Z, Van Kampen KR, Tang DC. Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza. PLoS ONE 2011; 6:e22605; http://dx.doi.org/10.1371/journal.pone.0022605; PMID: 21818346
   PubMed Web of Science ®Google Scholar
• Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, Chen DT, et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005; 23:1029 - 36; http://dx.doi.org/10.1016/j.vaccine.2004.07.043; PMID: 15620476
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009; 8:447 - 54; http://dx.doi.org/10.1586/erv.09.4; PMID: 19348560
   PubMed Web of Science ®Google Scholar
• Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science 2010; 329:52 - 6; http://dx.doi.org/10.1126/science.1190719; PMID: 20488990
   PubMed Web of Science ®Google Scholar
• Hitchman RB, Locanto E, Possee RD, King LA. Optimizing the baculovirus expression vector system. Methods 2011; 55:52 - 7; http://dx.doi.org/10.1016/j.ymeth.2011.06.011; PMID: 21945427
   PubMed Web of Science ®Google Scholar
• Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008; 66:655 - 63; http://dx.doi.org/10.1007/s00239-008-9119-z; PMID: 18504518
   PubMed Web of Science ®Google Scholar
• Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010; 28:Suppl 4 D45 - 53; http://dx.doi.org/10.1016/j.vaccine.2010.08.028; PMID: 20713260
   PubMed Web of Science ®Google Scholar
• Meijer A, Meerhoff TJ, Meuwissen LE, van der Velden J, Paget WJ. Epidemiological and virological assessment of influenza activity in Europe during the winter 2005-2006. Euro Surveill 2007; 12:E11 - 2; PMID: 17991413
   PubMedGoogle Scholar
• Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U. Trivalent and quadrivalent MF59((R))-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study. Vaccine 2011; 29:8696 - 704; http://dx.doi.org/10.1016/j.vaccine.2011.08.111; PMID: 21906647
   PubMed Web of Science ®Google Scholar
• Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011; 10:1131 - 41; http://dx.doi.org/10.1586/erv.11.73; PMID: 21854309
   PubMed Web of Science ®Google Scholar
• Hennessy AV, Davenport FM. Relative merits of aqueous and adjuvant influenza vaccines when used in a two-dose schedule. Public Health Rep 1961; 76:411 - 9; http://dx.doi.org/10.2307/4591160; PMID: 13713365
   PubMed Web of Science ®Google Scholar
• Salk JE, Bailey ML, Laurent AM. The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water in-oil emulsion. Am J Hyg 1952; 55:439 - 56; PMID: 14933383
   PubMed Web of Science ®Google Scholar
• Salk JE, Contakos M, Laurent AM, Sorensen M, Rapalski AJ, Simmons IH, et al. Use of adjuvants in studies on influenza immunization. III. Degree of persistence of antibody in human subjects two years after vaccination. J Am Med Assoc 1952; 151:1169 - 75; PMID: 13034453
   PubMed Web of Science ®Google Scholar
• Davis DJ, Philip RN, Bell JA, Vogel JE, Jensen DV. Epidemiologic studies on influenza in familial and general population groups. 1951-1956. III. Laboratory observations. Am J Hyg 1961; 73:138 - 47; PMID: 13720154
   PubMed Web of Science ®Google Scholar
• Davenport FM, Hennessy AV, Bell JA. Immunologic advantages of emulsified influenza virus vaccines. Mil Med 1962; 127:95 - 100; PMID: 13883722
   PubMed Web of Science ®Google Scholar
• Beebe GW, Simon AH, Vivona S. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am J Epidemiol 1972; 95:337 - 46; PMID: 5015584
   PubMed Web of Science ®Google Scholar
• Davenport FM, Hennessy AV, Askin FB. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol 1968; 100:1139 - 40; PMID: 5648476
   PubMed Web of Science ®Google Scholar
• Werner J, Kuwert EK, Stegmaier R, Simbock H. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza. II. Neuraminidase inhibiting antibodies (author's transl)]. Zentralbl Bakteriol A 1980; 246:1 - 9; PMID: 7424233
   PubMedGoogle Scholar
• D'Errico MM, Grasso GM, Romano F, Montanaro D. [Comparison of anti-influenza vaccines: whole adsorbed trivalent, trivalent subunit and tetravalent subunit]. Boll Ist Sieroter Milan 1988; 67:283 - 9; PMID: 2482767
   PubMedGoogle Scholar
• Ioniţă E, Lupulescu E, Alexandrescu V, Matepiuc M, Constantinescu C, Cretescu L, et al. Comparative study of the immunogenicity of aqueous versus aluminium phosphate adsorbed split influenza vaccine C.I. Arch Roum Pathol Exp Microbiol 1989; 48:265 - 73; PMID: 2519636
   PubMedGoogle Scholar
• O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6:699 - 710; PMID: 17931151
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Fragapane E, Bugarini R, Hora M, Henriksson T, Palla E, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 2006; 13:1010 - 3; http://dx.doi.org/10.1128/CVI.00191-06; PMID: 16960112
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24:3063 - 5; http://dx.doi.org/10.1016/j.vaccine.2006.01.015; PMID: 16464520
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26:1525 - 9; http://dx.doi.org/10.1016/j.vaccine.2008.01.019; PMID: 18294741
   PubMed Web of Science ®Google Scholar
• Camilloni B, Neri M, Lepri E, Iorio AM. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 2009; 27:4099 - 103; http://dx.doi.org/10.1016/j.vaccine.2009.04.078; PMID: 19410623
   PubMed Web of Science ®Google Scholar
• Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10:639 - 51; http://dx.doi.org/10.1517/14712591003724662; PMID: 20218923
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28:4123 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.04.030; PMID: 20433807
   PubMed Web of Science ®Google Scholar
• Baldo V, Baldovin T, Pellegrini M, Angiolelli G, Majori S, Floreani A, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010; 2010:517198; PMID: 20369059
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19:2673 - 80; http://dx.doi.org/10.1016/S0264-410X(00)00499-0; PMID: 11257408
   PubMed Web of Science ®Google Scholar
• Puig-Barberà J, Di´ez-Domingo J, Varea A, Chavarri G, Rodrigo J, Hoyos S, et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 2007; 25:7313 - 21; http://dx.doi.org/10.1016/j.vaccine.2007.08.039; PMID: 17889411
   PubMed Web of Science ®Google Scholar
• Mannino S, Villa M, Weiss N, Apolone G, Rothman K. Effectiveness of influenza vaccination with Fluad versus a sub-unit influenza vaccine. Am J Epidemiol 2010; 171:S157
   Web of Science ®Google Scholar
• Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197:667 - 75; http://dx.doi.org/10.1086/527489; PMID: 18260764
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 2009; 4:e4384; http://dx.doi.org/10.1371/journal.pone.0004384; PMID: 19197383
   PubMed Web of Science ®Google Scholar
• Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010; 64:432 - 8; http://dx.doi.org/10.1111/j.1742-1241.2009.02309.x; PMID: 20039974
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008; 359:1631 - 3; http://dx.doi.org/10.1056/NEJMc0805274; PMID: 18843132
   PubMed Web of Science ®Google Scholar
• Galli G, Hancock K, Hoschler K, DeVos J, Praus M, Bardelli M, et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 2009; 106:7962 - 7; http://dx.doi.org/10.1073/pnas.0903181106; PMID: 19416838
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant. Pediatr Infect Dis J 2009; 28:563 - 71; http://dx.doi.org/10.1097/INF.0b013e31819d6394; PMID: 19561422
   PubMed Web of Science ®Google Scholar
• Vesikari T, Knuf M, Wutzler P.. Efficacy of an MF59- Adjuvanted seasonal influenza vaccine versus non-adjuvanted influenza vaccine and control vaccine in 6 to < 72 month old children. 2010.
   Google Scholar
• Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365:1406 - 16; http://dx.doi.org/10.1056/NEJMoa1010331; PMID: 21995388
   PubMed Web of Science ®Google Scholar
• Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines 2009; 8:483 - 92; http://dx.doi.org/10.1586/erv.09.5; PMID: 19348563
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Clement F, Leroux-Roels I, Drame M, Moris P, Devaster JM. Adjuvanted influenza vaccines improve anti-influenza cellular mediated immunity impaired in elderly. Presented at: Influenza Vaccines for the World, October 18–20, 2006; Vienna, Austria 2006.
   Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461 - 73; http://dx.doi.org/10.1016/j.vaccine.2011.01.011; PMID: 21256188
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 2009; 8:401 - 23; http://dx.doi.org/10.1586/erv.09.15; PMID: 19348557
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91 - 101; http://dx.doi.org/10.1016/S1473-3099(10)70296-6; PMID: 21168369
   PubMed Web of Science ®Google Scholar
• Meier S, Bel M, L'Huillier A, Crisinel PA, Combescure C, Kaiser L, et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 2011; 29:3548 - 57; http://dx.doi.org/10.1016/j.vaccine.2011.02.094; PMID: 21419775
   PubMed Web of Science ®Google Scholar
• Rahier JF, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011; 60:456 - 62; http://dx.doi.org/10.1136/gut.2010.233981; PMID: 21270121
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Welfare Finland. National narcolespy task force interim report. Helsinki, Finland, 2011.
   Google Scholar
• World Health Organization. Global Advisory Committee on Vaccine Safety. Statement on narcolepsy and vaccination. Geneva: WHO, 2011.
   Google Scholar
• Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, Lin L, et al. Post-H1N1 narcolepsy-cataplexy. Sleep 2010; 33:1428 - 30; PMID: 21102981
   PubMed Web of Science ®Google Scholar
• Tsai TF, Crucitti A, Nacci P, Nicolay U, Della Cioppa G, Ferguson J, et al. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011; 43:702 - 6; PMID: 21534891
   PubMed Web of Science ®Google Scholar
• Poland GA, Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn A, Vandermeulen C, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:629 - 31; http://dx.doi.org/10.1086/590913; PMID: 18694337
   PubMed Web of Science ®Google Scholar
• Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR, et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 2009; 30:325 - 33; http://dx.doi.org/10.1016/j.it.2009.05.004; PMID: 19541535
   PubMed Web of Science ®Google Scholar
• Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 2009; 10:73 - 86; http://dx.doi.org/10.2165/00128071-200910020-00001; PMID: 19222248
   PubMed Web of Science ®Google Scholar
• Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979; 69:1247 - 51; http://dx.doi.org/10.2105/AJPH.69.12.1247; PMID: 507256
   PubMed Web of Science ®Google Scholar
• Brown H, Kasel JA, Freeman DM, Moise LD, Grose NP, Couch RB. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J Infect Dis 1977; 136:Suppl S466 - 71; http://dx.doi.org/10.1093/infdis/136.Supplement_3.S466; PMID: 606768
   PubMed Web of Science ®Google Scholar
• Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J Infect Dis 1979; 140:234 - 8; http://dx.doi.org/10.1093/infdis/140.2.234; PMID: 479641
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286 - 94; http://dx.doi.org/10.1056/NEJMoa043555; PMID: 15525713
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295 - 301; http://dx.doi.org/10.1056/NEJMoa043540; PMID: 15525714
   PubMed Web of Science ®Google Scholar
• Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007; 25:659 - 63; http://dx.doi.org/10.1016/j.vaccine.2006.08.026; PMID: 17011678
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6614 - 9; http://dx.doi.org/10.1016/j.vaccine.2008.09.078; PMID: 18930093
   PubMed Web of Science ®Google Scholar
• Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009; 7:13; http://dx.doi.org/10.1186/1741-7015-7-13; PMID: 19341446
   PubMed Web of Science ®Google Scholar
• Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454 - 9; http://dx.doi.org/10.1016/j.vaccine.2008.10.077; PMID: 19022318
   PubMed Web of Science ®Google Scholar
• Gelinck LB, van den Bemt BJ, Marijt WA, van der Bijl AE, Visser LG, Cats HA, Rimmelzwaan GF, et al. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 2009; 27:2469 - 74; PMID: 19368788
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25:6755 - 63; http://dx.doi.org/10.1016/j.vaccine.2007.06.066; PMID: 17692438
   PubMed Web of Science ®Google Scholar
• Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K, et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 2002; 20:1099 - 105; http://dx.doi.org/10.1016/S0264-410X(01)00440-6; PMID: 11803070
   PubMed Web of Science ®Google Scholar
• Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008; 168:2405 - 14; http://dx.doi.org/10.1001/archinternmed.2008.513; PMID: 19064822
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650 - 8; http://dx.doi.org/10.1086/590434; PMID: 18652550
   PubMed Web of Science ®Google Scholar
• Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10:134; http://dx.doi.org/10.1186/1471-2334-10-134; PMID: 20504306
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther 2011; 11:415 - 27; http://dx.doi.org/10.1517/14712598.2011.557658; PMID: 21299438
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666 - 74; http://dx.doi.org/10.1016/j.vaccine.2011.06.010; PMID: 21699951
   PubMed Web of Science ®Google Scholar
• Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine 2010; 28:3025 - 9; http://dx.doi.org/10.1016/j.vaccine.2009.10.152; PMID: 19931380
   PubMed Web of Science ®Google Scholar
• Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, et al. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin Vaccine Immunol 2011; 18:647 - 54; http://dx.doi.org/10.1128/CVI.00435-10; PMID: 21288996
   PubMed Web of Science ®Google Scholar
• Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16:915 - 20; http://dx.doi.org/10.1038/nm.2182; PMID: 20639891
   PubMed Web of Science ®Google Scholar
• Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC, et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 2007; 6:809 - 19; http://dx.doi.org/10.1586/14760584.6.5.809; PMID: 17931160
   PubMed Web of Science ®Google Scholar
• Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371:2019 - 25; http://dx.doi.org/10.1016/S0140-6736(08)60839-9; PMID: 18554712
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Hammond SA, Ellingsworth LR, Glenn GM. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J Virol 2004; 78:7610 - 8; http://dx.doi.org/10.1128/JVI.78.14.7610-7618.2004; PMID: 15220436
   PubMed Web of Science ®Google Scholar
• Frech SA, Kenney RT, Spyr CA, Lazar H, Viret JF, Herzog C, et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005; 23:946 - 50; http://dx.doi.org/10.1016/j.vaccine.2004.06.036; PMID: 15603897
   PubMed Web of Science ®Google Scholar
• Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80:4962 - 70; http://dx.doi.org/10.1128/JVI.80.10.4962-4970.2006; PMID: 16641287
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896 - 903; http://dx.doi.org/10.1056/NEJMoa030595; PMID: 14985487
   PubMed Web of Science ®Google Scholar
• Bodewes R, Kreijtz JH, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, et al. Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation. Am J Pathol 2011; 179:30 - 6; http://dx.doi.org/10.1016/j.ajpath.2011.03.026; PMID: 21640972
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009; 4:e6999; http://dx.doi.org/10.1371/journal.pone.0006999; PMID: 19756141
   PubMed Web of Science ®Google Scholar
• Amorij JP, Hinrichs W, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect Dis 2010; 10:699 - 711; http://dx.doi.org/10.1016/S1473-3099(10)70157-2; PMID: 20883966
   PubMed Web of Science ®Google Scholar
• Schild GC, Wood JM, Newman RW. A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 1975; 52:223 - 31; PMID: 816480
   PubMed Web of Science ®Google Scholar
• Johannsen R, Hinz J, Gruschkau H. Pitfalls of single radial immunodiffusion techniques used for the quantification of influenza haemagglutinin. Dev Biol Stand 1986; 65:255 - 60; PMID: 3104116
   PubMedGoogle Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424 - 35; PMID: 19745215
   PubMed Web of Science ®Google Scholar
• Kapteyn JC, Porre AM, de Rond EJ, Hessels WB, Tijms MA, Kessen H, et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009; 27:1468 - 77; http://dx.doi.org/10.1016/j.vaccine.2008.11.113; PMID: 19110022
   PubMed Web of Science ®Google Scholar
• Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, et al. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Vaccine 2011; 29:3377 - 89; http://dx.doi.org/10.1016/j.vaccine.2011.02.090; PMID: 21397719
   PubMed Web of Science ®Google Scholar
• Williams TL, Luna L, Guo Z, Cox NJ, Pirkle JL, Donis RO, et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008; 26:2510 - 20; http://dx.doi.org/10.1016/j.vaccine.2008.03.014; PMID: 18440105
   PubMed Web of Science ®Google Scholar
• Li C, Jaentschke B, Song Y, Wang J, Cyr TD, Van Domselaar G, et al. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc 2010; 5:14 - 9; http://dx.doi.org/10.1038/nprot.2009.200; PMID: 20010723
   PubMed Web of Science ®Google Scholar
• Nilsson CE, Abbas S, Bennemo M, Larsson A, Hamalainen MD, Frostell-Karlsson A. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010; 28:759 - 66; http://dx.doi.org/10.1016/j.vaccine.2009.10.070; PMID: 19857452
   PubMed Web of Science ®Google Scholar
• Hendry RM, Herrmann JE. Detection and identification of influenza virus antigens by nylon-coupled enzyme-linked immunoassay. J Virol Methods 1983; 6:9 - 17; http://dx.doi.org/10.1016/0166-0934(83)90063-0; PMID: 6339533
   PubMed Web of Science ®Google Scholar
• Legastelois I, Chevalier M, Bernard MC, de Montfort A, Fouque M, Pilloud A, et al. Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines. J Virol Methods 2011; 178:129 - 36; http://dx.doi.org/10.1016/j.jviromet.2011.08.027; PMID: 21907241
   PubMed Web of Science ®Google Scholar
• Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 2007; 3:157 - 64; http://dx.doi.org/10.4161/hv.3.5.4175; PMID: 17637571
   PubMed Web of Science ®Google Scholar
• Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, et al. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009; 27:6512 - 21; http://dx.doi.org/10.1016/j.vaccine.2009.08.053; PMID: 19729082
   PubMed Web of Science ®Google Scholar
• Wraith DC, Vessey AE, Askonas BA. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 1987; 68:433 - 40; http://dx.doi.org/10.1099/0022-1317-68-2-433; PMID: 3493324
   PubMed Web of Science ®Google Scholar
• Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, Nason M, et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE 2010; 5:e9812; http://dx.doi.org/10.1371/journal.pone.0009812; PMID: 20352112
   PubMed Web of Science ®Google Scholar
• Plotnicky H, Cyblat-Chanal D, Aubry JP, Derouet F, Klinguer-Hamour C, Beck A, et al. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology 2003; 309:320 - 9; http://dx.doi.org/10.1016/S0042-6822(03)00072-2; PMID: 12758178
   PubMed Web of Science ®Google Scholar
• Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, Banet-Noach C, et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009; 27:2099 - 107; http://dx.doi.org/10.1016/j.vaccine.2009.02.011; PMID: 19356612
   PubMed Web of Science ®Google Scholar
• Taylor PM, Askonas BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 1986; 58:417 - 20; PMID: 2426185
   PubMed Web of Science ®Google Scholar
• Sui Z, Chen Q, Fang F, Zheng M, Chen Z. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 2010; 28:7690 - 8; http://dx.doi.org/10.1016/j.vaccine.2010.09.019; PMID: 20870054
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13 - 7; http://dx.doi.org/10.1056/NEJM198307073090103; PMID: 6602294
   PubMed Web of Science ®Google Scholar
• Russell SM, Liew FY. T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin. Nature 1979; 280:147 - 8; http://dx.doi.org/10.1038/280147a0; PMID: 317881
   PubMed Web of Science ®Google Scholar
• Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008; 451:591 - 5; http://dx.doi.org/10.1038/nature06531; PMID: 18235503
   PubMed Web of Science ®Google Scholar
• Stouffer AL, Acharya R, Salom D, Levine AS, Di Costanzo L, Soto CS, et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008; 451:596 - 9; http://dx.doi.org/10.1038/nature06528; PMID: 18235504
   PubMed Web of Science ®Google Scholar
• De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008; 283:11382 - 7; http://dx.doi.org/10.1074/jbc.M800650200; PMID: 18252707
   PubMed Web of Science ®Google Scholar
• Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci USA 2010; 107:12658 - 63; http://dx.doi.org/10.1073/pnas.0911806107; PMID: 20615945
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598 - 605; PMID: 15100303
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157 - 63; http://dx.doi.org/10.1038/13484; PMID: 10502819
   PubMed Web of Science ®Google Scholar
• Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002; 83:1851 - 9; PMID: 12124449
   PubMed Web of Science ®Google Scholar
• Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29:5145 - 52; http://dx.doi.org/10.1016/j.vaccine.2011.05.041; PMID: 21624416
   PubMed Web of Science ®Google Scholar
• AGGLUTINATION-INHIBITION test proposed as a standard of reference in influenza diagnostic studies; Committee on Standard Serological Procedures in Influenza Studies. J Immunol 1950; 65:347 - 53; PMID: 14774517
   PubMed Web of Science ®Google Scholar
• Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci USA 2011; 108:14216 - 21; http://dx.doi.org/10.1073/pnas.1111497108; PMID: 21825125
   PubMed Web of Science ®Google Scholar
• Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, et al. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 2009; 5:e1000350; http://dx.doi.org/10.1371/journal.ppat.1000350; PMID: 19300497
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246 - 51; http://dx.doi.org/10.1126/science.1171491; PMID: 19251591
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011; 333:843 - 50; http://dx.doi.org/10.1126/science.1204839; PMID: 21737702
   PubMed Web of Science ®Google Scholar
• Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265 - 73; http://dx.doi.org/10.1038/nsmb.1566; PMID: 19234466
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850 - 6; http://dx.doi.org/10.1126/science.1205669; PMID: 21798894
   PubMed Web of Science ®Google Scholar
• Okuno Y, Matsumoto K, Isegawa Y, Ueda S. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 1994; 68:517 - 20; PMID: 8254764
   PubMed Web of Science ®Google Scholar
• Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, Friesen RH, et al. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J Infect Dis 2009; 200:1870 - 3; http://dx.doi.org/10.1086/648378; PMID: 19911992
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. M Bio 2010; 1:18 - 10; PMID: 20689752
   PubMedGoogle Scholar
• Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med 2011; 1:a007278
   PubMed Web of Science ®Google Scholar
• Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060 - 4; http://dx.doi.org/10.1126/science.1192517; PMID: 20647428
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916 - 924; PMID: 21975270
   PubMed Web of Science ®Google Scholar
• Corti D, Suguitan AL Jr., Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 2010; 120:1663 - 73; http://dx.doi.org/10.1172/JCI41902; PMID: 20389023
   PubMed Web of Science ®Google Scholar
• Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181 - 93; http://dx.doi.org/10.1084/jem.20101352; PMID: 21220454
   PubMed Web of Science ®Google Scholar